Evidence map›Paper›PMID 25764003›Full record

ArticlePloS one2015

Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays.

Xiaohong R Yang, J Keith Killian, Sue Hammond, Laura S Burke, Hunter Bennett, Yonghong Wang, Sean R Davis, Louise C Strong, Joseph Neglia, Marilyn Stovall and 6 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xiaohong R YangDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
J Keith KillianCenter of Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Sue HammondDepartment of Laboratory Medicine and Pathology, Children's Hospital and Ohio State University College of Medicine, Columbus, Ohio, United States of America.
Laura S BurkeDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Hunter BennettDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Yonghong WangCenter of Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Sean R DavisCenter of Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Louise C StrongDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Joseph NegliaDepartment of Pediatrics, University of Minnesota School of Medicine, Minneapolis, Minnesota, United States of America.
Marilyn StovallDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Rita E WeathersDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Leslie L RobisonEpidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Smita BhatiaDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Kiyohiko MabuchiDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Peter D InskipDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Paul MeltzerCenter of Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7M
Molecular Profiling of Clinical SpecimensZICBC011040 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI EDELMAN, DANIEL · 2009 to 2020
$25.5M
Cancer Genomics Technology DevelopmentZIABC011091 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MELTZER, PAUL S. · 2009 to 2025
$16.9M
NCI NIH HHS P30 CA016672NCI NIH HHS U24 CA055727NCI NIH HHS U24 CA55727
6 · The paper itself

Abstract

Ionizing radiation is an established risk factor for breast cancer. Epidemiologic studies of radiation-exposed cohorts have been primarily descriptive; molecular events responsible for the development of radiation-associated breast cancer have not been elucidated. In this study, we used array comparative genomic hybridization (array-CGH) to characterize genome-wide copy number changes in breast tumors collected in the Childhood Cancer Survivor Study (CCSS). Array-CGH data were obtained from 32 cases who developed a second primary breast cancer following chest irradiation at early ages for the treatment of their first cancers, mostly Hodgkin lymphoma. The majority of these cases developed breast cancer before age 45 (91%, n = 29), had invasive ductal tumors (81%, n = 26), estrogen receptor (ER)-positive staining (68%, n = 19 out of 28), and high proliferation as indicated by high Ki-67 staining (77%, n = 17 out of 22). Genomic regions with low-copy number gains and losses and high-level amplifications were similar to what has been reported in sporadic breast tumors, however, the frequency of amplifications of the 17q12 region containing human epidermal growth factor receptor 2 (HER2) was much higher among CCSS cases (38%, n = 12). Our findings suggest that second primary breast cancers in CCSS were enriched for an "amplifier" genomic subgroup with highly proliferative breast tumors. Future investigation in a larger irradiated cohort will be needed to confirm our findings.

Indexed as

DNA Copy Number VariationsAdultAdult Survivors of Child Adverse EventsBreast NeoplasmsChromosomes, Human, Pair 17Comparative Genomic HybridizationErb-b2 Receptor Tyrosine KinasesFemaleGene AmplificationHumansMiddle AgedNeoplasms, Radiation-InducedNeoplasms, Second PrimaryYoung AdultERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID25764003
PMCPMC4357472

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.